Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -638.59% | 133.63% | 36.86% | 11.04% | -30.26% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -100.00% | -97.81% | 259.14% | -- |
| Total Other Non-Cash Items | 158.38% | -10.19% | -60.00% | -91.87% | 1,313.84% |
| Change in Net Operating Assets | 261.85% | -337.85% | 74.36% | -304.15% | 94.19% |
| Cash from Operations | 25.11% | 55.83% | 32.23% | -89.16% | 20.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -34.87% | -39.45% | 91.99% | -342.15% | -40.98% |
| Issuance of Common Stock | -78.57% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -105.88% | -- | -100.00% | -- | -- |
| Cash from Financing | -97.27% | 8,167.77% | -100.90% | 289.37% | 1,525.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -120.95% | 231.74% | -203.53% | 769.22% | 85.59% |